Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept
开发用于快速、经济生产肽的新型生物工艺平台
基本信息
- 批准号:7848987
- 负责人:
- 金额:$ 37.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-04 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAmino AcidsBacteriaBindingBiological AssayBiological ProductsBiomedical ResearchCellsChemicalsChimeric ProteinsChitinChromatographyComplexCulture MediaDevelopmentDextransEndotoxinsEpitopesEscherichia coliFermentationGeneric DrugsGrowthHigh Pressure Liquid ChromatographyHistidineIn VitroIndustryInsulinIonsKilogramKnock-outLaboratoriesLengthMetalsMethodsMonitorN-terminalNatureNucleic AcidsPeptide HydrolasesPeptide SynthesisPeptidesPhasePlant ResinsPreparationProcessProductionProteinsQuality ControlReactionReagentRecombinantsRecoveryResearchSolubilityStreptavidinSystemTechnologyTemperatureTestingVaccinesWorkaqueousbiodefensebioprocesschemical synthesiscommercial applicationcommercializationcostcost efficientdextranin vivomaltose-binding proteinmeetingsnovelnovel strategiespeptide chemical synthesispressurepreventpublic health relevancerecombinant peptidescale uptherapeutic vaccinetoolwasting
项目摘要
DESCRIPTION (provided by applicant): A novel bioprocess platform, involving synthesis of peptide and protein biopharmaceutical products as fusions with a synthetic "anchor" protein in bacteria, and subsequent proteolytic cleavage, has been developed. The unique features of the system allow for the economical production of large quantities of simple linear peptides, as well as complex, multi-component peptides. Preliminary studies and cost projections suggest that peptides ranging from about 15 to 100 amino acids can be produced for a few dollars per gram, in contrast to chemical synthetic methods for which costs dramatically increase with the length of the peptide product. Another major advantage is the rapidity with which each product can be generated and the generic nature of the process for many peptide and protein products, facilitating scale-up. This novel, rapid, economical bioprocess platform for recombinant peptides and proteins can help meet production requirements, at all levels of production from research quantities to many kilograms, in the biopharmaceutical, vaccine, biodefense, and biomedical research industries. PUBLIC HEALTH RELEVANCE: A novel production platform is being developed and specifically tailored for the rapid, scaleable, and economical synthesis of large peptides and small proteins for which chemical synthesis and existing recombinant methods are not feasible. The technology addresses a significant unmet need for production of peptide product candidates in the 20-100 amino acid size range. There are numerous commercial applications for this technology in manufacturing of peptide therapeutics and vaccines, in conformational epitope discovery and production (for biodefense), and in biomedical research. The platform may even be cost efficient enough to help retain bio-manufacturing capacity in the US, despite the pressures of cheaper labor and operating costs elsewhere in the global economy. The platform also represents an environmentally friendly alternative to chemical peptide synthesis, which generates large volumes of organic waste.
描述(由申请人提供):已经开发了一个新的生物工艺平台,涉及合成多肽和蛋白质生物制药产品,作为与细菌中合成的“锚”蛋白的融合,以及随后的蛋白水解裂解。该系统的独特功能允许经济生产大量简单的线性肽,以及复杂的多组分肽。初步研究和成本预测表明,生产15到100个氨基酸的肽每克只需几美元,而化学合成方法的成本则随着肽产品的长度而急剧增加。另一个主要优点是每个产品都可以快速生成,并且许多肽和蛋白质产品的过程具有通用性质,便于扩大规模。这种新型、快速、经济的重组肽和蛋白质生物工艺平台可以帮助满足生物制药、疫苗、生物防御和生物医学研究行业从研究数量到数公斤的所有生产水平的生产要求。公共卫生相关性:正在开发一种新的生产平台,专门用于快速、可扩展和经济地合成化学合成和现有重组方法无法实现的大肽和小蛋白质。该技术解决了在20-100个氨基酸大小范围内生产肽候选产品的重大未满足需求。这项技术在多肽疗法和疫苗的制造、构象表位的发现和生产(用于生物防御)以及生物医学研究方面有许多商业应用。尽管全球经济中其他地方的劳动力和运营成本更低,但该平台甚至可能具有足够的成本效益,有助于保留美国的生物制造能力。该平台也代表了一种环境友好的替代化学肽合成,产生大量的有机废物。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Spiral counter-current chromatography of small molecules, peptides and proteins using the spiral tubing support rotor.
- DOI:10.1016/j.chroma.2011.06.007
- 发表时间:2011-09-09
- 期刊:
- 影响因子:0
- 作者:Knight M;Finn TM;Zehmer J;Clayton A;Pilon A
- 通讯作者:Pilon A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
APRILE L PILON其他文献
APRILE L PILON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('APRILE L PILON', 18)}}的其他基金
Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction
重组人 CC10 蛋白用于治疗和预防慢性同种异体肺移植功能障碍
- 批准号:
10602077 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Role of Secretoglobin 1A1 Protein in COVID-19-induced Thrombosis
分泌球蛋白 1A1 蛋白在 COVID-19 诱导的血栓形成中的作用
- 批准号:
10255855 - 财政年份:2021
- 资助金额:
$ 37.5万 - 项目类别:
Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept
开发用于快速、经济生产肽的新型生物工艺平台
- 批准号:
7325568 - 财政年份:2007
- 资助金额:
$ 37.5万 - 项目类别:
Recombinant CC10 for treatment of meconium aspiration
重组 CC10 用于治疗胎便误吸
- 批准号:
6645573 - 财政年份:2003
- 资助金额:
$ 37.5万 - 项目类别:
Optimum Dose of rhCC10 for Lung Protection in IRDS
rhCC10 保护 IRDS 肺部的最佳剂量
- 批准号:
6344251 - 财政年份:2001
- 资助金额:
$ 37.5万 - 项目类别:
RECOMBINANT HUMAN CC10 AND NOTCH-1 ANTAGONIST IN NSCLC
非小细胞肺癌 (NSCLC) 中的重组人类 CC10 和 NOTCH-1 拮抗剂
- 批准号:
6143475 - 财政年份:2000
- 资助金额:
$ 37.5万 - 项目类别:
RECOMBINANT HUMAN CC10 FOR PREVENTION OF NEONATAL BPD
用于预防新生儿 BPD 的重组人 CC10
- 批准号:
2616435 - 财政年份:1998
- 资助金额:
$ 37.5万 - 项目类别:
RECOMBINANT HUMAN CC10 FOR PREVENTION OF NEONATAL BPD
用于预防新生儿 BPD 的重组人 CC10
- 批准号:
6017162 - 财政年份:1998
- 资助金额:
$ 37.5万 - 项目类别:
UBIQUITIN FUSION FOR PEPTIDE IMMUNE DISPLAY AND VACCINES
用于肽免疫展示和疫苗的泛素融合
- 批准号:
2076869 - 财政年份:1996
- 资助金额:
$ 37.5万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 37.5万 - 项目类别:
Continuing Grant














{{item.name}}会员




